MOTS-c Storage and Stability: Why the Product Label Controls

A Peptide Name Is Not a Stability Study

Storage advice must describe a particular material in a particular container. “MOTS-c” may refer to a free base or acetate form, a dry bulk ingredient, a lyophilized preparation, or an aqueous compounded product with different excipients and concentrations. Those are not interchangeable stability objects.

FDA’s July 2026 chemistry review explains the governing principle:

“Product formulation is critical to the quality and stability of peptide drug products.”

The issuer is the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research. This 12-word excerpt is not a storage instruction; it explains why a generic 21-, 28-, or 30-day rule cannot be transferred across formulations (FDA, Evaluation of MOTS-c-Related Bulk Drug Substances, section II.A.2.a, PDF page 16).

The Storage-Evidence Ladder

The higher source controls the decision. If the label and a generic webpage disagree, the webpage does not override the product record.

What FDA’s MOTS-c Review Actually Contains

The FDA briefing reports storage statements from a nominator-provided certificate of analysis and a commercial supplier page for MOTS-c acetate. It then emphasizes that peptides are sensitive to formulation, process, pH, temperature, concentration, impurities, and excipients, and that multiple analytical methods may be needed to detect aggregates (FDA briefing, PDF pages 15–16).

Those supplier statements do not establish a shelf life for a finished, patient-dispensed injectable product. They do not describe every concentration, bacteriostatic or sterile diluent, stopper, vial, transport history, puncture pattern, or compounding process.

The same FDA review says the stability, pharmacologic activity, and immunogenic properties of MOTS-c-related peptides are highly sensitive to manufacturing and finished-product quality attributes. That is why “small peptide” and sequence-based oxidation theories cannot produce reliable discard arithmetic.

Beyond-Use Date Is Not the Same as Expiration Date

USP General Chapter 797 describes minimum standards for compounded sterile preparations, including preparations made by reconstituting or altering a bulk drug substance. A beyond-use date begins from preparation and reflects factors that include formulation, container-closure compatibility, environment, sterilization or aseptic process, testing, packaging, and temperature (USP Chapter 797).

An expiration date on a conventionally manufactured product is supported by the manufacturer’s stability program for that specific product. FDA describes it as the period in which strength, quality, and purity are known to remain stable under labeled conditions (FDA, Expiration Dates—Questions and Answers).

Neither concept authorizes a consumer to extend a pharmacy-assigned date because a vial remains clear.

Why the Legacy Numbers Were Not Defensible

The previous page assigned 24-plus months to dry MOTS-c, 21–28 days after reconstitution, exact pH and container preferences, daily room-temperature potency losses, overnight-excursion equivalence, freeze-thaw penalties, and six-to-eight-month frozen-aliquot life. It also supplied reconstitution and aliquoting instructions.

The cited literature was generic peptide chemistry or unrelated experimental work. It did not test the actual finished formulations readers might receive. A degradation mechanism can explain what to measure; it does not establish how fast a particular product changes or whether it remains sterile.

Likewise, the mouse and cell studies that characterize MOTS-c biology did not validate consumer storage instructions (PMID 25738459; PMCID PMC4350682).

A Temperature-Excursion Record

If a product was left out, overheated, frozen unexpectedly, exposed to light, transported without temperature control, or stored beyond the label, record:

1. Exact pharmacy, product name, formulation, concentration, lot, and beyond-use date.
2. Labeled storage range and protection instructions.
3. Highest and lowest known temperatures and how they were measured.
4. Duration of the excursion and whether it happened more than once.
5. Whether the vial was still sealed, reconstituted, or previously punctured.
6. Any cloudiness, particles, discoloration, damaged seal, leakage, or other change.

Give that record to the dispensing pharmacy. Do not translate “overnight” into a fixed number of lost days, and do not assume that freezing rescues a product.

What Appearance Can—and Cannot—Tell You

Visible particles, cloudiness, discoloration, leakage, or container damage are reasons not to use the product until the dispensing pharmacy has assessed it. A normal-looking vial is not proof of potency or sterility. Many chemical changes, microbial problems, and subvisible aggregates cannot be excluded by eye.

The rare-but-serious risk review explains why aggregation and immunogenicity are potential concerns rather than observed adverse-event rates. The young-adult evidence map addresses the missing administered-human denominator, and the creatine combination audit shows why separate evidence streams cannot validate product handling.

Medical review of this revision is pending. FDA, USP, investigators, authors, suppliers, pharmacies, and institutions do not endorse MOTS-c, HealthRX.com, or this page.